Categories Analysis, Retail

What to expect when Macy’s (M) reports Q2 2023 earnings

Macy’s has guided for adjusted EPS of $0.10-0.15 for Q2 2023

Shares of Macy’s, Inc. (NYSE: M) were down over 2% on Tuesday. The stock has dropped 25% year-to-date. The retailer is scheduled to report its second quarter 2023 earnings results on Tuesday, August 22, before market open. Here’s a look at what to expect from the earnings report:

Revenue

Macy’s has guided for net sales of $5.0-5.1 billion for the second quarter of 2023. Analysts are projecting revenue of $5.09 billion for Q2, which would represent a decline of 9% from the same period a year ago. In the first quarter of 2023, net sales declined 7% year-over-year to $5 billion.

Earnings

Macy’s has guided for adjusted EPS of $0.10-0.15 for Q2 2023. Analysts are forecasting EPS of $0.13 for Q2 which compares to $1.00 reported in the year-ago period. In Q1 2023, adjusted EPS fell to $0.56 from $1.08 in the prior-year period.

Points to note

Macy’s continues to be pressured by a challenging economic environment and shifts in consumer spending. Demand for discretionary categories weakened as customers moved their spending to food and essentials. Comparable sales fell 7.9% on an owned basis and 7.2% on an owned-plus-licensed basis. These pressures are expected to continue in the second quarter.

Gross margin in Q1 rose to 40% from 39.6% in the year-ago period. Merchandise margin remained flat, benefiting from lower clearance markdowns. In the second quarter, the company plans to implement deeper markdowns to clear its excess inventory, which is expected to lead to a drop in gross margin.

Macy’s is expected to benefit from its investments in private brands, small-format stores and Macy’s Marketplace. The company is seeing encouraging results from its small-format stores and remains optimistic about the opportunity in this space.

Most Popular

Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO

Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training

INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues

Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came

Riding the AI wave, Nvidia looks set to stay on the high-growth path

After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top